Loading...
BIOL.Q logo

BIOLASE, Inc.OTCPK:BIOL.Q Rapporto sulle azioni

Cap. di mercato US$274.5k
Prezzo delle azioni
US$0.000001
Il mio valore equo
Non disponibile
1Y-92.9%
7D9.6%
1D
Valore del portafoglio
​
Vista

BIOLASE, Inc.

Report azionario OTCPK:BIOL.Q

Capitalizzazione di mercato: US$274.5k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

BIOLASE (BIOL.Q) Panoramica del titolo

BIOLASE, Inc. insieme alle sue consociate, sviluppa, produce, commercializza e vende sistemi laser per dentisti e pazienti negli Stati Uniti e a livello internazionale. Maggiori dettagli

BIOL.Q analisi fondamentale
Punteggio fiocco di neve
Valutazione2/6
Crescita futura0/6
Prestazioni passate0/6
Salute finanziaria0/6
Dividendi0/6

Analisi del rischio

Non ha una capitalizzazione di mercato significativa ( $274K )

Patrimonio netto negativo

Prezzo delle azioni altamente volatile negli ultimi 3 mesi rispetto al mercato US

Gli utili sono diminuiti del 7.3% all'anno negli ultimi 5 anni

+ 2 più rischi

BIOL.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di BIOLASE, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per BIOLASE
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$0.0097
Massimo di 52 settimaneUS$0.26
Minimo di 52 settimaneUS$0.004
Beta0.82
Variazione di 1 mese4.28%
Variazione a 3 mesi21.88%
Variazione di 1 anno-92.93%
Variazione a 3 anni-100.00%
Variazione a 5 anni-100.00%
Variazione dall'IPO-100.00%

Notizie e aggiornamenti recenti

Recent updates

Seeking Alpha • Aug 31

Biolase partners with dental speciality programs across U.S.

Biolase (NASDAQ:BIOL) announced strategic plan to partner with postgraduate dental specialty programs throughout North America for dentists to adopt its Waterlase technology. "We believe investing in postgraduate programs will accelerate the adoption curve and be mutually beneficial. The residents will learn the benefits of all tissue laser technology in dentistry while providing the latest in patient care," the company said. The Waterlase dental laser offers faster procedures to less invasive treatment option.
Seeking Alpha • Jul 21

BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity

BIOLASE is a name we advocate investors to steer clear of in long-only, equity focused portfolios. The company displays numerous characteristics investors are agnostic to in FY22, particularly around profitability and equity beta. BIOL's earnings model sees it print ongoing operating losses and weak FCF conversion, requiring sustained capital injections for liquidity. We've priced the stock at $4 suggesting the market has it fairly valued. We are neutral on BIOLASE, Inc. (BIOL) shares and note the company is ill-positioned to deliver capital appreciation in the coming periods. BIOL's earnings model involves razor thin gross margins that feed minimal amounts of operating income to free cash below the bottom line. Hence, it prints a series of operating losses that require continuous external capital injection in order to maintain liquidity. A review of the company's products is best left for a separate review; hence, we will take a hard data approach to gauge the investment debate. We price BIOL at $4 per share, and note it displays numerous characteristics investors are shying away from in their positioning for FY23. We rate BIOL neutral. Exhibit 1. BIOL 6-month price action Data: Updata Market factors show divergence from equity premia Investors have finally wound back the high-beta trade of FY20/21' and are paying attention to quality and value factors once more. Fundamental momentum and earnings quality are more imperative than ever. Companies with proven market fit, strong economics, and above all, defensible business models have strengthened against benchmarks whilst reducing correlations in doing so. Later we demonstrate the weakness in BIOL's earnings model. However, it's abundantly clear BIOL displays a lack of the alternative premia investors are paying a premium for in FY22. Firstly, the stock has declined in relative strength against the benchmark sharply since April, as seen below. Meanwhile, after a small blip, its equity beta has remained substantially high at 1.2 indicating it is a high-beta play that will likely to have been punished this YTD. This much is true – BIOL has caught sellers all the way from $11, posting a 59% loss since January. Exhibit 2. BIOL has weakened against the benchmark as equity beta remains high – factors investors are agnostic to in FY22 Data: Updata Unsurprisingly, the stock has also weakened against the US medical devices and health care equipment sector since equity markets began to downturn in October 2021. As seen in Exhibit 3, BIOL now trades at a 12-month low relative to the sector. As investors step up in quality and resiliency, they will look to defensible characteristics and high return on capital amid the shifting rates regime. On this, BIOL lags and hence potentially explains the relative weakness to the traditionally defensive US medtech sector. Exhibit 3. BIOL continues to weaken against US medtech & health care equipment, as investors step up in quality in the space Data: Updata Fundamental Factors Don't Stack Up Q1 FY22 sales came in at ~$10 million, ~25% YoY growth. Performance was underlined by a 43% YoY gain to US laser systems and a 35% YoY gain to BIOLASE specific procedures. International turnover also grew 15% and have been steady for the last few quarters. On a marginal basis, the company lifted gross margin 13 percentage points to 47% – above pre-pandemic gross margin of 34%. This is still razor thin however, and leaves little headroom down the P&L for margin elasticity. On this, management notes it successfully passed costs through in Q1, printing operating expenses of ~$9 million, in line from last year. To achieve is guided 10% YoY revenue growth in FY22/23', BIOL has what it calls a 3-pronged strategy that's been in situ since 2021. Chief to the first 'prong' is specialist adoption of the laser technology. To this effect, BIOL formed an academy to market the dental lasers amongst orthodontists, endodontists and periodontists back in 2021. It did this to hopefully drive up the acceleration of new accounts, management said on the Q1 earnings call. Its second 'prong' is more of a speculative growth play at the US general practitioner dentist ("GPD") market, by our estimate. It notes there are ~150,000 of these generalists in the US, and makes some very generous assumptions around its ability to penetrate this segment. Per CEO John Beaver on the Q1 earnings call, "[i]f an additional 5% of GPDs adopted our laser in the US, it would generate $225 million in laser revenue, not including consumables," on the Q1 earnings call. Again, these are very generous assumptions around its addressable market that haven't yet begun to materialise. To get to $225 million from an additional 5% of GPD adoption, BIOL says it expanded its Waterlase Exclusive Trial program. This lets GPDs utilise the system in their office for ~45 days. Included is 2 days of in-person training and mentor support, all at no extra cost. Afterwards, the clinician is prompted to buy the laser. Firstly this is a timely and costly way of trying to convert GPDs. It takes longer than 1 30 day payment cycle and there's no incentive structure to use the device on trial. Moreover, conversion has been light on these events to date. It held 30 in FY21 and 12 so far this YTD. Each had 4–8 GPDs participate, management said, 9.5%–19% participation rate. The third 'prong' is driving the adoption of its lasers to corporate dentists. It has ongoing trials with 80% of the largest DSOs in the US, which targets new graduates as many new dentists are employed by the DSOs straight from dental school. BIOL hopes to educate them on using the lasers, and try and make lasers an "essential part of their practice moving forward". Hence, when out in practice, they might be drawn to BIOL lasers. Again, fraught with assumption, by estimate, and it relies on the premise these dentists will prefer BIOL lasers in the first place. There's no evidence to suggest this will be the case. In that vein, BIOL's profitability characteristics are an equity risk looking ahead. Investors have turned away from rewarding top-line growth in FY22 and are rewarding bottom-line fundamentals and profitability instead. Whilst it continues to build its top line at ~25% YoY, this doesn't pull through the P&L to earnings and FCF. As such, BIOL has printed a series of operating losses since FY15 to date, whilst realizing a negative FCF yield across this entire time span. Moreover, sales were extremely lumpy pre-Covid, and haven't grown back past these levels. Exhibit 4. Series of lumpy sales performance and operating losses sees weak FCF conversion
Seeking Alpha • Jul 01

BIOLASE amends senior secured term loan with SWK Funding

BIOLASE (NASDAQ:BIOL) has amended its senior secured term loan with SWK Funding LLC by extending the interest-only period of the loan by two quarters to November 2023 and reduces the minimum Consolidated Unencumbered Liquid Assets from $7,500,000 to $5,500,00. The company used a portion of the proceeds from its recent equity offering to prepay $1M of the outstanding loan balance. John Beaver, President and Chief Executive Officer of BIOLASE said, "This prepayment and amendment will result in lower interest expense while also increasing the Company's liquidity."
Seeking Alpha • Mar 21

BIOLASE: Bad News Across The Board - Sell

Company reports Q4 results in-line with preliminary numbers and provides a rather disappointing outlook. Profitability target delayed by another year. Muted growth in combination with the decision to keep pricing steady likely to result in another year of material cash usage. On the conference call, management affirmed its intent to conduct a reverse stock split before the May 23 deadline. With profitability delayed by another year and the likely requirement to raise additional capital in 2023, investors should consider selling existing positions ahead of the upcoming reverse stock split.
Articolo di analisi • Feb 24

Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Jan 11

BIOLASE - Speculative Buy After Strong Preliminary Q4 Results

Company releases very strong preliminary Q4 top-line numbers with revenues now eclipsing pre-COVID numbers. Despite solid execution, shares have retreated by 80% from recent highs as investors remain wary of ongoing cash usage and a potential reverse stock split to regain Nasdaq listing compliance. Biolase continues to burn sizeable amounts of cash with adjusted EBITDA profitability not expected before Q4/FY2022. Shares are trading at bargain levels at just 0.7x EV/Revenue. Despite poor market sentiment, highly speculative investors should consider a rebound trade in the shares given management's solid execution, bargain valuation and expectations for EBITDA profitability at the end of the year.
Seeking Alpha • Nov 24

BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors

Company continues to outperform expectations as sales and margins recover from last year's COVID-related setback. Despite solid execution, shares have retreated by more than 70% from recent highs as investors remain wary of a potential reverse stock split to regain Nasdaq listing compliance. Biolase continues to burn sizeable amounts of cash with adjusted EBITDA profitability not expected before Q4/FY2022. Stock looks cheap from a fundamental perspective, trading at just 1.25x EV/Revenue. On Tuesday, Biolase announced another 180-day Nasdaq extension and improved credit terms with its primary lender thus providing a major catalyst for the beaten down shares but only the most speculative investors/traders you consider scaling into the shares at current levels given ongoing cash burn and the likely requirement to execute a reverse stock split next year.

Rendimenti per gli azionisti

BIOL.QUS Medical EquipmentUS Mercato
7D9.6%4.4%1.1%
1Y-92.9%-17.9%28.7%

Ritorno vs Industria: BIOL.Q ha avuto una performance inferiore rispetto al US Medical Equipment che ha registrato un rendimento -17.9 % nell'ultimo anno.

Rendimento vs Mercato: BIOL.Q ha avuto una performance inferiore al mercato US che ha registrato un rendimento 28.7 % nell'ultimo anno.

Volatilità dei prezzi

Is BIOL.Q's price volatile compared to industry and market?
BIOL.Q volatility
BIOL.Q Average Weekly Movement33.9%
Medical Equipment Industry Average Movement8.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di BIOL.Q è stato volatile rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale ( 34% ) di BIOL.Q è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
1984157John Beaverwww.biolase.com

BIOLASE, Inc. insieme alle sue consociate, sviluppa, produce, commercializza e vende sistemi laser per dentisti e pazienti negli Stati Uniti e a livello internazionale. I suoi sistemi laser dentali consentono a dentisti, parodontologi, endodontisti, dentisti pediatrici, chirurghi orali e altri specialisti del settore di eseguire una serie di procedure odontoiatriche minimamente invasive, tra cui applicazioni cosmetiche, restaurative e chirurgiche complesse. L'azienda offre sistemi laser dentali Waterlase per tutti i tessuti per il taglio di tessuti molli e duri; sistemi laser a diodi per tessuti molli, igiene, sollievo temporaneo dal dolore, sbiancamento dei denti e procedure cosmetiche; e il laser Epic Hygiene per gestire la parodontite non chirurgica e migliorare la produzione clinica.

BIOLASE, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di BIOLASE con la sua capitalizzazione di mercato?
BIOL.Q statistiche fondamentali
Capitalizzazione di mercatoUS$274.48k
Utili (TTM)-US$15.97m
Ricavi(TTM)US$46.03m
0.0x
Rapporto P/S
0.0x
Rapporto P/E

BIOL.Q è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
BIOL.Q Conto economico (TTM)
RicaviUS$46.03m
Costo del fatturatoUS$30.18m
Profitto lordoUS$15.85m
Altre speseUS$31.82m
Utili-US$15.97m

Ultimi utili riportati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)-0.44
Margine lordo34.44%
Margine di profitto netto-34.69%
Rapporto debito/patrimonio netto-486.1%

Come si è comportato BIOL.Q nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2025/03/12 22:55
Prezzo dell'azione a fine giornata2025/03/12 00:00
Utili2024/09/30
Utili annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

BIOLASE, Inc. è coperta da 8 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Edward WooAscendiant Capital Markets LLC
Bruce JacksonBenchmark Company
Kyle BauserColliers Securities